logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics CEO looks ahead to clinical trial next year and prospects for RNAi

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), sat down with Proactive London's Andrew Scott after taking on the role back in August.

Silence expects to kick off its first-in-human clinical trial in the second half of next year.

The company specialises in RNA interference – a type of treatment which works by suppressing, or ‘silencing’, genes that are thought to cause diseases.

Quick facts: Silence Therapeutics PLC

Price: 256 GBX

AIM:SLN
Market: AIM
Market Cap: £200.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Silence Therapeutics hits first milestone in Mallinckrodt deal

Silence Therapeutics PLC's (LON:SLN) David Solomon speaks to Proactive London's Andrew Scott soon after announcing they've hit the first milestone in their deal with Mallinckrodt Pharmaceuticals - triggering a US$2mln research payment. The UK specialist in RNA therapeutics has already...

3 weeks ago

2 min read